Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug hopes to restore arm movement after spinal injury

NCT ID NCT04683848

Disease control Sponsor: Tanabe Pharma America, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called MT-3921 (Unasnemab) in 72 people with recent severe neck spinal cord injuries. The goal was to see if it could improve arm and hand function better than a placebo. Participants received the drug or placebo by IV over 6 months, and their motor scores were measured.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MT-3921 (Unasnemab)
What this could lead to
If it works, this could point toward a treatment that improves arm and hand function after a severe neck spinal cord injury.
What could go wrong
This is a small, early-phase trial with only 72 people. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

72 people

The number who actually took part.

Started

Aug 2021

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Additional screening criteria check may apply for qualification: * Provide written informed consent prior to beginning any study procedures * Cervical spinal cord injury that meet all of the following criteria: * Classified as AIS A, AIS B or AIS C * ISNCSCI neurological level of injury between C4 and C7 (for C4, the subject must have at least 1 point of motor activity between C5 to C7) * UEMS ≤28 at Screening * Body mass index (BMI) \<40 Exclusion Criteria: Additional screening criteria check may apply for qualification: * Any concomitant injury that interferes with the procedures and examinations required by study protocol, including performance, interpretation or validity of neurological examinations * Poly-traumatic Injury as defined by Injury Severity Score (ISS) values \> 25 * Penetrating spinal cord injuries * Complete transection of the spinal cord * Any other significant pre-existing medical conditions prior to spinal cord injury or current conditions that, in the judgement of the iInvestigator, may increase the risks associated with study participation * History of anaphylaxis or clinically significant allergic reactions to any medication * History or presence of malignancy within the last 3 years prior to screening * Subjects with current SARS-CoV-2 infection (COVID-19) * Subjects with hereditary fructose intolerance * Psychoactive substance use disorder * Participation in any clinical trial of a new chemical entity within 12 weeks prior to Screening * Female subjects who are pregnant or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal cord injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spinal cord injury

Contacts and locations

Locations

  • Augusta University

    Augusta, Georgia, 30912, United States

  • Brooke Army Medical Center in San Antonio

    Houston, Texas, 78234, United States

  • Carilion Clinic

    Roanoke, Virginia, 24014, United States

  • Carolinas Rehabilitation

    Charlotte, North Carolina, 28203, United States

  • Gifu University Hospital

    Gifu, Gifu, 501-1194, Japan

  • Hokkaido Spinal Cord Injury Center

    Bibai-shi, Hokkaido, 072-0015, Japan

  • Japan Organization of Occupational Health and Safety SPINAL INJURIES CENTER

    Izuka-shi, Fukuoka, 820-8508, Japan

  • Japanese Red Cross Kobe Hospital

    Kobe, Hyōgo, 651-0073, Japan

  • Medical College of Wisconsin - Froedtert Hospital

    Milwaukee, Wisconsin, 53226, United States

  • Murayama Medical Center

    Musashimurayama-shi, Tokyo, 208-0011, Japan

  • NSHA-Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, B3H3A7, Canada

  • National Hospital Organization Kumamoto Medical Center

    Kumamoto, Kumamoto, 860-0008, Japan

  • Oregon Health and Science University - Center for Health & Healing

    Portland, Oregon, 97239, United States

  • Saint Louis University Hospital

    St Louis, Missouri, 63110, United States

  • Spectrum Health

    Grand Rapids, Michigan, 49503, United States

  • Tallahassee Neurological Clinic

    Tallahassee, Florida, 32308, United States

  • The Ottawa Hospital

    Ottawa, Ontario, K1Y4E9, Canada

  • The University of Texas Health Science Center at San Antonio

    San Antonio, Texas, 78229, United States

  • University of California Irvine

    Orange, California, 92868, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45219, United States

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.